EULAV Asset Management Has $28.54 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL

EULAV Asset Management lowered its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 3.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 49,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. EULAV Asset Management owned approximately 0.22% of Madrigal Pharmaceuticals worth $28,535,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MDGL. Flagship Harbor Advisors LLC acquired a new stake in Madrigal Pharmaceuticals during the fourth quarter worth approximately $29,000. Aventura Private Wealth LLC bought a new position in Madrigal Pharmaceuticals in the fourth quarter worth approximately $36,000. Aster Capital Management DIFC Ltd bought a new position in Madrigal Pharmaceuticals in the third quarter worth approximately $39,000. Quarry LP bought a new stake in shares of Madrigal Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Johnson Financial Group Inc. bought a new stake in shares of Madrigal Pharmaceuticals during the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on MDGL. Wells Fargo & Company upgraded Madrigal Pharmaceuticals to an “overweight” rating in a report on Monday. Evercore set a $649.00 price objective on Madrigal Pharmaceuticals in a report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, April 21st. Citigroup restated a “market outperform” rating on shares of Madrigal Pharmaceuticals in a report on Monday. Finally, Bank of America decreased their price objective on Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating for the company in a report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $687.00.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock opened at $486.98 on Friday. The business’s fifty day simple moving average is $516.90 and its 200 day simple moving average is $513.93. The firm has a market capitalization of $11.23 billion, a P/E ratio of -38.05 and a beta of -1.07. Madrigal Pharmaceuticals, Inc. has a 12 month low of $275.00 and a 12 month high of $615.00. The company has a current ratio of 3.50, a quick ratio of 3.16 and a debt-to-equity ratio of 0.63.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) EPS for the quarter, topping analysts’ consensus estimates of ($3.61) by $0.36. The business had revenue of $311.34 million for the quarter, compared to analyst estimates of $301.05 million. Madrigal Pharmaceuticals had a negative return on equity of 50.15% and a negative net margin of 27.32%.Madrigal Pharmaceuticals’s quarterly revenue was up 126.8% compared to the same quarter last year. During the same period last year, the company posted ($3.32) earnings per share. As a group, analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.23 EPS for the current year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, insider David Soergel sold 1,042 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the sale, the insider directly owned 10,033 shares in the company, valued at $4,973,759.42. The trade was a 9.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the completion of the sale, the director owned 22,015 shares in the company, valued at approximately $11,347,411.60. The trade was a 20.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,568 shares of company stock worth $3,880,711 over the last quarter. 17.60% of the stock is currently owned by corporate insiders.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.